Clinical research of chronic lymphocytic leukaemia (CLL) has been advancing at an unprecedented pace. Several randomized studies in the current era of oral targeted agents seem to have skipped one step and proceeded directly to combinations with antibodies, omitting the testing of novel-agent monotherapy. Thus, the ibrutinib + rituximab combination was used as the experimental arm in a major trial for untreated fit patients while two other trials subsequently showed that addition of rituximab to ibrutinib does not produce any meaningful benefit. Similarly, two large trials omitted venetoclax monotherapy and proceeded directly to venetoclax + rituximab or obinutuzumab versus chemoimmunotherapy. While such trials are undoubtedly cheaper, quicker and easier to manage, they leave the CLL community with uncertainty regarding the real role of the monoclonal antibody components. Thus, we are left with regimens which are undoubtedly effective, but might actually be unnecessarily toxic and expensive. The solution to this problem is simple: future randomized trials should be carefully designed in a 'step by step' fashion which would provide the CLL community with simple yet robust answers regarding efficacy of novel regimens so that these can be introduced to practice following the best principles of evidence-based medicine.

4th Department of Internal Medicine Haematology University Hospital and Faculty of Medicine Hradec Králové Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc21025771

003      

CZ-PrNML

005      

20211026133527.0

007      

ta

008      

211013s2021 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1111/bjh.17215 $2 doi

035    __

$a (PubMed)33216352

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Smolej, Lukáš $u 4th Department of Internal Medicine -Haematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic

245    10

$a Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia / $c L. Smolej

520    9_

$a Clinical research of chronic lymphocytic leukaemia (CLL) has been advancing at an unprecedented pace. Several randomized studies in the current era of oral targeted agents seem to have skipped one step and proceeded directly to combinations with antibodies, omitting the testing of novel-agent monotherapy. Thus, the ibrutinib + rituximab combination was used as the experimental arm in a major trial for untreated fit patients while two other trials subsequently showed that addition of rituximab to ibrutinib does not produce any meaningful benefit. Similarly, two large trials omitted venetoclax monotherapy and proceeded directly to venetoclax + rituximab or obinutuzumab versus chemoimmunotherapy. While such trials are undoubtedly cheaper, quicker and easier to manage, they leave the CLL community with uncertainty regarding the real role of the monoclonal antibody components. Thus, we are left with regimens which are undoubtedly effective, but might actually be unnecessarily toxic and expensive. The solution to this problem is simple: future randomized trials should be carefully designed in a 'step by step' fashion which would provide the CLL community with simple yet robust answers regarding efficacy of novel regimens so that these can be introduced to practice following the best principles of evidence-based medicine.

650    _2

$a adenin $x analogy a deriváty $x terapeutické užití $7 D000225

650    _2

$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971

650    _2

$a bicyklické sloučeniny heterocyklické $x terapeutické užití $7 D019086

650    _2

$a lidé $7 D006801

650    _2

$a chronická lymfatická leukemie $x farmakoterapie $7 D015451

650    _2

$a piperidiny $x terapeutické užití $7 D010880

650    12

$a randomizované kontrolované studie jako téma $7 D016032

650    _2

$a rituximab $x terapeutické užití $7 D000069283

650    _2

$a sulfonamidy $x terapeutické užití $7 D013449

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a přehledy $7 D016454

773    0_

$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 193, č. 4 (2021), s. 723-726

856    41

$u https://pubmed.ncbi.nlm.nih.gov/33216352 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20211013 $b ABA008

991    __

$a 20211026133533 $b ABA008

999    __

$a ok $b bmc $g 1714694 $s 1146278

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 193 $c 4 $d 723-726 $e 20201120 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374

LZP    __

$a Pubmed-20211013